RE:“Second mouse gets the cheese “It is apparent that inthno keeps trying to obscure the fact that ..... ONCY’s planned Phase 3 clinical trial involving pelareorep in combination with the PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) as a first line therapy in advanced/metastatic pancreatic cancer, and following CG Oncology’s intended Phase 3 clinical trial results submission for an FDA Biologics License Application in bladder cancer, should make ONCY’s pelareorep in PDAC a hot item, as the 2nd CPI + OV combination on the market in a what is considered to be a very difficult cancer with an unmet treatment need. The FDA will have gained enough experience with OVs + CPIs by then to look at ONCY’s much more favorable light as an addition to this class of biological therapies.